CG Oncology
CGON
Market cap $1.84B

24.17 USD

-0.01

0.04%

At close May 14, 4:00 PM EDT

After hours

24.17

+0.00

0.00%

1 day

-0.04%

5 days

6.71%

1 month

20.49%

3 months

-15.25%

6 months

-31.92%

Year to date

-16.57%

1 year

-11.53%

5 years

-34.97%

10 years

-34.97%

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113

Healthcare Biotechnology

0

Funds holding %

of 7,425 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

531% more call options, than puts

Call options by funds: $6.49M | Put options by funds: $1.03M

119% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 27

118% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 17

16% more funds holding

Funds holding: 121 [Q3] → 140 (+19) [Q4]

10.58% more ownership

Funds ownership: 77.79% [Q3] → 88.38% (+10.58%) [Q4]

9% more funds holding in top 10

Funds holding in top 10: 11 [Q3] → 12 (+1) [Q4]

3% less capital invested

Capital invested by funds: $1.96B [Q3] → $1.9B (-$67.1M) [Q4]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$23

5%

downside

Avg. target

$56

132%

upside

High target

$75

210%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

JP Morgan Brian Cheng 29% 1-year accuracy 5 / 17 met price target	70%upside $41	Overweight Initiated	2 May 2025
RBC Capital Gregory Renza 22% 1-year accuracy 17 / 78 met price target	181%upside $68	Outperform Maintained	29 Apr 2025
Cantor Fitzgerald Josh Schimmer 25% 1-year accuracy 14 / 55 met price target	210%upside $75	Overweight Reiterated	28 Apr 2025
HC Wainwright & Co. Andres Maldonado 22% 1-year accuracy 11 / 51 met price target	210%upside $75	Buy Reiterated	28 Apr 2025
Scotiabank	5%downside $23	Sector Perform Initiated	16 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about CGON published over the past 30 days

Zacks Investment Research

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the first quarter ended March 31, 2025, and provided business updates.

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Zacks Investment Research

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks Investment Research

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?

CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Investors Business Daily

CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug

Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.

CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74.5% CR rate in the BOND-003 trial and a 41.2% CR rate in a phase 1 trial for MIBC. A basic DCF valuation estimates CGON's enterprise value at $5.3bn, suggesting a price target of $69, about 3x the current price.

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Zacks Investment Research

Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

See News Rankings

Charts implemented using Lightweight Charts™